With Hereditary Factor X Deficiency…
One in a Million COULD BE ONE OF YOUR PATIENTS
COAGADEX Is the First and Only Treatment Specifically for Hereditary Factor X Deficiency
- COAGADEX is high purity—94% factor X1
- Single-factor plasma-derived factor X concentrate is the only treatment recommended by the National Hemophilia Foundation's Medical and Scientific Advisory Council (MASAC) for hereditary factor X deficiency. COAGADEX is the only approved single-factor treatment available2
In Clinical Studies, COAGADEX Was Proven Effective for3-8:
Support for You and Your Patients with Factor X Deficiency
References: 1. Data on file, BPL-RD050-0515. 2. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation. MASAC Document #276. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-276-masac-recommendations-concerning-products-licensed-for-the-treatment-of-hemophilia-and-selected-disorders-of-the-coagulation-system. Accessed May 31, 2023. 3. Liesner R, et al. Haemophilia. 2018;24(6):941-949. 4. Austin S, et al. Haemophilia. 2016;22:419-425. 5. Huang JN, et al. Res Pract Thromb Haemost. 2021;5(5):e12550. 6. Austin SK, et al. Haemophilia. 2016;22:419-425. 7. Kulkarni R, et al. J Thromb Haemost. 2018;16:849-857. 8. Escobar M, et al. Haemophilia. 2016;22:713-720.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency
Contraindication for COAGADEX
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
